Brought to you by 
Novartis, HGS end late-stage hepatitis C deal
Jun 2006
Executive Summary
Novartis has licensed exclusive worldwide rights to Human Genome Sciences' Albuferon (albumin-interferon alpha 2b), a Phase II candidate for chronic hepatitis C. The companies will co-promote Albuferon in the US, sharing commercialization costs in this territory; Novartis pays commercialization fees in all other areas.
Deal Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis, HGS end late-stage hepatitis C deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice